Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An investigation of the correlation between blood concentration of mizoribine and its efficacy in treatment of rheumatoid arthritis based on indices of drug survival and improvement in DAS28-CRP.
Ohtsubo H, Ohkura S, Akimoto M, Arishima Y, Sunahara N, Izumihara T, Eiraku N, Yoshitama T, Matsuda T. Ohtsubo H, et al. Among authors: yoshitama t. Mod Rheumatol. 2012 Nov;22(6):837-43. doi: 10.1007/s10165-012-0611-3. Epub 2012 Mar 6. Mod Rheumatol. 2012. PMID: 22391858
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M; Iguratimod-Clinical Study Group. Ishiguro N, et al. Mod Rheumatol. 2013 May;23(3):430-9. doi: 10.1007/s10165-012-0724-8. Epub 2012 Jul 26. Mod Rheumatol. 2013. PMID: 22833377 Clinical Trial.
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K; Iguratimod-Clinical Study Group. Hara M, et al. Mod Rheumatol. 2014 May;24(3):410-8. doi: 10.3109/14397595.2013.843756. Epub 2013 Nov 7. Mod Rheumatol. 2014. PMID: 24252050 Clinical Trial.
Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.
Mori S, Yoshitama T, Hidaka T, Sakai F, Hasegawa M, Hashiba Y, Suematsu E, Tatsukawa H, Mizokami A, Yoshizawa S, Hirakata N, Ueki Y. Mori S, et al. Among authors: yoshitama t. PLoS One. 2017 Jun 8;12(6):e0179179. doi: 10.1371/journal.pone.0179179. eCollection 2017. PLoS One. 2017. PMID: 28594905 Free PMC article.
Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan.
Endo Y, Koga T, Kawashiri SY, Morimoto S, Nishino A, Okamoto M, Eguchi M, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Ueki Y, Yoshitama T, Eiraku N, Matsuoka N, Okada A, Fujikawa K, Hamada H, Tsuru T, Nagano S, Arinobu Y, Hidaka T, Tada Y, Kawakami A. Endo Y, et al. Among authors: yoshitama t. Scand J Rheumatol. 2020 Jan;49(1):13-17. doi: 10.1080/03009742.2019.1627411. Epub 2019 Aug 12. Scand J Rheumatol. 2020. PMID: 31402744
Significance of anti-Ro/SSA antibodies in the response and retention of abatacept in patients with rheumatoid arthritis: a multicentre cohort study.
Endo Y, Koga T, Kawashiri SY, Morimoto S, Nishino A, Okamoto M, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Ueki Y, Yoshitama T, Eiraku N, Matsuoka N, Okada A, Fujikawa K, Hamada H, Tsuru T, Nagano S, Arinobu Y, Hidaka T, Tada Y, Kawakami A. Endo Y, et al. Among authors: yoshitama t. Scand J Rheumatol. 2021 Jan;50(1):15-19. doi: 10.1080/03009742.2020.1772361. Epub 2020 Sep 3. Scand J Rheumatol. 2021. PMID: 32880228
49 results